Program
Ivermectin
Also written as “ivermectin”, “Ivermectin cream” and “CD5024”.
Its studies are mostly in Rosacea · COVID-19 · Lice Infestations · Dermatitis, Atopic · Acne Vulgaris, led by 14 companies.
Drug pageIvermectin: every studyMany companies study it; this page follows only the 28 they lead. All 163 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Galderma Groupits history only | 60 open or running | phase 4since Nov 24, 2015 | Dec 14, 2011 | none ahead |
| Johnson & Johnsonits history only | 40 open or running | phase 3since Jan 8, 2009 | Jan 8, 2009 | none ahead |
| Topaz Pharmaceuticalsits history only | 40 open or running | phase 3since Feb 8, 2010 | Oct 1, 2009 | none ahead |
| Humanis Saglık Anonim Sirketiits history only | 20 open or running | phase 1since Sep 13, 2021 | Sep 13, 2021 | none ahead |
| MedinCell S.Aits history only | 20 open or running | phase 2since Mar 28, 2022 | Oct 26, 2020 | none ahead |
| Sun Pharmaceutical Industriesits history only | 20 open or running | phase 1since May 3, 2017 | May 3, 2017 | none ahead |
| Genuine Research Center, Egyptits history only | 10 open or running | phase 1since Apr 18, 2021 | Apr 18, 2021 | none ahead |
| Infectopharm Arzneimittelits history only | 10 open or running | phase 3since Sep 28, 2021 | Sep 28, 2021 | none ahead |
| Insud Pharmaits history only | 10 open or running | phase 3since Aug 8, 2023 | Aug 8, 2023 | none ahead |
| Mayne Pharma International Pty | 10 open or running | phase 3since Oct 30, 2017 | Oct 30, 2017 | none ahead |
| Padagisits history only | 10 open or running | phase 3since Jun 6, 2016 | Jun 6, 2016 | none ahead |
| Teva Pharmaceutical Industriesits history only | 10 open or running | phase 3since Jul 19, 2016 | Jul 19, 2016 | none ahead |
| United Laboratoriesits history only | 10 open or running | phase 2since Sep 14, 2017 | Sep 14, 2017 | none ahead |
| Zydus Lifesciencesits history only | 10 open or running | phase 3since Sep 25, 2019 | Sep 25, 2019 | none ahead |
Also a collaborator on its studies: Eva Pharma and bioRASI.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Mayne Pharma International Pty only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 30, 2017First study: phase 3 study in Head LiceFirst studyNCT03337490 · 296 enrolled · United States
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“Glutamate-gated chloride channel modulator; Glutamate-gated chloride channel modulator”ChEMBL 37, by rule
Studies
The one study Mayne Pharma International Pty leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT03337490Head Lice · United States | 3 | Completed | Dec 4, 2017 | 296 |
How it is read
Names in the registry
- “Ivermectin”, 4 entries
- “ivermectin”, 4 entries
- “Ivermectin cream”, 2 entries
- “CD5024”, 2 entries
- “0.5% Ivermectin Cream”, 2 entries
Conditions, from the studies’ own filings
- Rosacea, 9 studies
- COVID-19, 4 studies
- Lice Infestations, 3 studies
- Dermatitis, Atopic, 1 study
- Acne Vulgaris, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.